8-K: Presidio Property Trust Reports Q1 2024 Results with Increased Revenue but Higher Net Loss

Presidio Property Trust announced its first quarter 2024 financial results, showing increased revenue but a larger net loss compared to the same period last year.

Summary

• Presidio Property Trust reported a net loss of approximately $5.8 million, or ($0.47) per share, for the three months ended March 31, 2024, compared to a net loss of approximately $1.5 million, or $(0.13) per share, for the same period in 2023.
• Total revenues increased to approximately $4.8 million for the first quarter of 2024, up from approximately $4.1 million in the first quarter of 2023.
• The company's net real estate assets were approximately $135.3 million as of March 31, 2024, compared to approximately $133.9 million as of March 31, 2023.
• A non-cash impairment charge of approximately $0.1 million was recognized related to four model homes.
• Model home transaction fees increased by $95k in Q1 2024 compared to Q1 2023, with 27 model home sales in 2024 versus three in 2023, resulting in a gain of $2.0 million and $0.4 million respectively.
• The fair value of investments in Conduit Pharmaceuticals decreased by approximately $3.9 million during the quarter.
• FFO (Funds From Operations) decreased to approximately $(971,367) from $(228,914) year-over-year.
• Core FFO decreased to approximately $(429,445) from approximately $31,932 year-over-year.
• The company acquired five model homes for approximately $2.2 million and sold 27 model homes for approximately $14.0 million.
• No dividends were declared for Series A Common Stock for the quarter ended March 31, 2024, compared to $0.022 per share in 2023, while Series D Preferred Stock dividends remained consistent at $0.58593 per share.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the increased net loss, decreased FFO and Core FFO, and the significant loss on the Conduit Pharmaceuticals investment. While there are some positives, such as increased revenue and model home sales, the overall financial performance is concerning.

Positives

• Total revenues increased year-over-year, indicating growth in the company's operations.
• Model home sales saw a significant increase, leading to a substantial gain on sales of real estate.
• The company signed leasing transactions totaling 24,476 square feet, including new leases and renewals.
• Scheduled lease expirations for 2024 are nearly half of those in 2023, suggesting a more stable rent roll for the year.

Negatives

• The net loss attributable to common stockholders increased significantly to $5.8 million, compared to $1.5 million in the same quarter of the previous year.
• The company experienced a $3.9 million loss on its investment in Conduit Pharmaceuticals marketable securities.
• FFO and Core FFO both decreased year-over-year, indicating a decline in operational performance.
• A non-cash impairment charge of $0.1 million was recognized related to four model homes.
• No dividends were declared for Series A Common Stock for the quarter ended March 31, 2024, compared to $0.022 per share in 2023.

Risks

• The company's financial performance is susceptible to changing market conditions in the geographic areas where its properties are located.
• The company's investment in Conduit Pharmaceuticals is subject to market fluctuations, as evidenced by the $3.9 million loss in Q1 2024.
• The company's reliance on model home sales and transaction fees makes it vulnerable to changes in the housing market.
• The company's FFO and Core FFO are limited as measures of performance due to the exclusion of depreciation, amortization, and changes in property values.

Future Outlook

The company anticipates a more stable rent roll through the end of 2024 due to lower scheduled lease expirations compared to 2023, despite uncertainty in the commercial real estate market. The company also notes that forward-looking statements are subject to risks and uncertainties.

Management Comments

• Gary Katz, the Company's Chief Investment Officer, stated that '2024 is off to a good start' and anticipates a more stable rent roll due to lower lease expirations.

Industry Context

The report reflects the challenges faced by REITs in the current commercial real estate market, including fluctuations in property values and the impact of market conditions on investment portfolios. The company's focus on model homes and geographically clustered properties is a specific strategy within the broader REIT landscape.

Comparison to Industry Standards

• Presidio's performance is mixed when compared to other REITs. While the increase in revenue is a positive sign, the significant net loss and decrease in FFO and Core FFO are concerning.
• Companies like American Tower (AMT) and Prologis (PLD), which are large-cap REITs, have shown more stable financial performance in recent quarters, though they operate in different sectors.
• Smaller REITs focused on specific niches, such as model homes, may experience more volatility, as seen in Presidio's results.
• The loss on the Conduit Pharmaceuticals investment highlights the risks of non-core investments for REITs, which typically focus on real estate assets.

Stakeholder Impact

• Shareholders will be negatively impacted by the increased net loss and decreased FFO and Core FFO.
• Employees may be concerned about the company's financial performance and its potential impact on job security.
• Customers and suppliers may be affected by any changes in the company's operations or financial stability.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Key Dates

Keywords

Real Estate Investment Trust, REIT, Model Homes, Commercial Real Estate, Financial Results, Net Loss, Revenue, FFO, Core FFO, Leasing, Impairment, Dividends